Th17细胞因子:COPD发病与急性加重的潜在新治疗靶点
本文综述IL-17和IL-22在慢阻肺病理生理中的作用。疾病起始与进展阶段,IL-17分泌增加引起中性粒细胞募集,导致慢性炎症、气道阻塞和肺气肿;疾病established阶段,IL-22反应缺陷促进病原体相关感染和急性加重。细胞因子产生异常涉及复杂免疫细胞网络和抗原提呈细胞功能障碍。文章讨论了这些发现对COPD管理和未来治疗策略的意义。
要点
- IL-17分泌增加在COPD起始和进展中驱动中性粒细胞募集,导致慢性炎症、气道阻塞和肺气肿
- COPDestablished阶段IL-22反应缺陷促进病原体相关感染和疾病急性加重
- IL-17和IL-22产生异常涉及复杂免疫细胞网络和抗原提呈细胞功能障碍
核心结论
- IL-17和IL-22在COPD病理生理中分别参与疾病起始进展和急性加重阶段,是潜在治疗靶点。
研究设计与样本
- 综述,描述IL-17和IL-22在COPD稳定期和急性加重期病理生理中作用及治疗意义。
主要发现
- 疾病起始和进展中IL-17分泌增加引起中性粒细胞募集,导致慢性炎症、气道阻塞和肺气肿。
- COPDestablished阶段IL-22反应缺陷促进病原体相关感染和疾病急性加重。
- IL-17和IL-22产生异常涉及复杂免疫细胞网络和抗原提呈细胞功能障碍。
临床怎么用
- 文章讨论IL-17和IL-22相关发现对COPD管理和未来治疗策略的意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease of the airways caused mainly by cigarette smoke exposure. COPD progression is marked by exacerbations of the disease, often associated with infections. Recent data show the involvement in COPD pathophysiology of interleukin (IL)-17 and IL-22, two cytokines that are important in the control of lung inflammation and infection. During the initiation and progression of the disease, increased IL-17 secretion causes neutrophil recruitment, leading to chronic inflammation, airways obstruction and emphysema. In the established phase of COPD, a defective IL-22 response facilitates pathogen-associated infections and disease exacerbations. Altered production of these cytokines involves a complex network of immune cells and dysfunction of antigen-presenting cells. In this review, we describe current knowledge on the involvement of IL-17 and IL-22 in COPD pathophysiology at steady state and during exacerbations, and discuss implications for COPD management and future therapeutic approaches.
引用
- Le Rouzic O, Pichavant M, Frealle E, et al. Th17 cytokines: novel potential therapeutic targets for COPD pathogenesis and exacerbations. Eur Respir J. 2017. PMID: 29025886. doi:10.1183/13993003.02434-2016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。